Toripalimab Plus Bevacizumab and Chemotherapy as Neoadjuvant Therapy in Advanced MSI-H or dMMR Colorectal Cancer
Status:
Recruiting
Trial end date:
2023-12-24
Target enrollment:
Participant gender:
Summary
This is a trial investigating the efficacy and safety of Toripalimab combined with
bevacizumab and chemotherapy as neoadjuvant therapy in patients with advanced microsatellite
instability-high (MSI-H) or DNA mismatch repair-deficient (dMMR) colorectal cancer.